Ivonescimab Receives NMPA Approval for 1L Treatment of PD-L1-Positive NSCLC, Based on Ph 3 Trial Demonstrating Superior Efficacy Over Keytruda April 30, 2025
Ph 3 AdvanTIG-302 trial unlikely to meet primary endpoint; Ociperlimab (BGB-A1217) Program to be discontinued April 16, 2025
Ph 3 DeLLphi-304 trial of IMDELLTRA (tarlatamab-dlle) in SCLC patients met primary endpoint at a planned interim analysis April 16, 2025
Imfinzi-based perioperative regimen approved in the EU for resectable NSCLC based on AEGEAN Ph 3 trial results April 8, 2025
European Commission approves SC RYBREVANT (amivantamab) for the treatment of patients with advanced EGFR-mutated NSCLC April 8, 2025
RYBREVANT (amivantamab-vmjw) + LAZCLUZE (lazertinib) outperform osimertinib with a significant OS benefit in patients with EGFR-mutated NSCLC April 2, 2025
In LAURA Ph 3 trial, Tagrisso continues to demonstrate improved OS trend in unresectable, Stage III setting April 2, 2025
Both Prolonged Median OS and Long Tail of Survival in Ph 2a Trial of CAN-2409 in Advanced NSCLC Patients Non-Responsive to ICI Treatment Reported April 2, 2025
Positive CHMP Opinion for Neoadjuvant Opdivo + Chemo Followed by Surgery and Adjuvant Opdivo for Resectable NSCLC in Patients with Tumor Cell PD-L1 Expression ≥1% April 2, 2025
Ph 3 Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab published in The Lancet March 11, 2025
Plans announced for Ph 2 trial of stenoparib + temozolomide for the treatment of recurrent SCLC March 11, 2025
Imfinzi-based perioperative regimen recommended for approval in the EU by CHMP for resectable NSCLC March 4, 2025
Neoadjuvant Opdivo® + Chemo Demonstrate Statistically Significant and Clinically Meaningful OS in Resectable NSCLC February 25, 2025
Zongertinib receives Priority Review from US FDA for the treatment of HER2-mutant advanced NSCLC February 25, 2025
IDEAYA and Gilead Sciences to Evaluate Combination of Trodelvy and IDE397 in MTAP-Deletion NSCLC February 19, 2025
Immuneering’s Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab) Announced February 11, 2025
Positive updated data from THIO-101 pivotal Ph 2 trial of THIO + Libtayo in patients with advanced NSCLC who failed two or more SOC regimens announced February 11, 2025
US FDA Grants Orphan Drug Designation to 225Ac-SSO110 (satoreotide) for the treatment of patients with SCLC February 11, 2025
